AstraZeneca completes exclusive license deal for ZEGFROVY
AstraZeneca (AZN) announced the successful completion of its previously announced exclusive license agreement with Dizal Pharmaceutical Co., Ltd for ZEGFROVY (sunvozertinib), an oral irreversible EGFR inhibitor for lung cancer patients.
AstraZeneca NYSE:AZN today announced the successful completion of the previously announced exclusive license agreement with Dizal Pharmaceutical Co., Ltd for ZEGFROVY® (sunvozertinib), an oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer.Through this…